GOSSGossamer Bio, Inc.

Nasdaq gossamerbio.com


$ 0.72 $ -0.02 (-3 %)    

Monday, 13-May-2024 15:57:55 EDT
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 0.72
$ 0.74
$ 0.00 x 0
$ 0.00 x 0
$ 0.72 - $ 0.74
$ 0.45 - $ 1.88
1,362,076
na
162.53M
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-03-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-22-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-gossamer-bio-maintains-4-price-target

Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.

 gossamer-bio-q1-eps-019-misses-018-estimate

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18...

 gossamer-bio-collaborates-with-italian-drugmaker-chiesi-to-advance-lung-health-solutions-worldwide

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hyperte...

 hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

 gossamer-bio-secures-160m-partnership-with-chiesi-group-to-accelerate-development-of-pulmonary-hypertension-treatment-486m-potential-for-seralutinib-collaboration

Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development an...

 wedbush-assumes-gossamer-bio-at-outperform-announces-price-target-of-4

Wedbush analyst Laura Chico assumes Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $4.

 piper-sandler-maintains-overweight-on-gossamer-bio-maintains-15-price-target

Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and maintains $15 price target.

 goldman-sachs-maintains-buy-on-gossamer-bio-lowers-price-target-to-8

Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $9 to $8.

 wedbush-reiterates-outperform-on-gossamer-bio-maintains-6-price-target

Wedbush analyst Andreas Argyrides reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $6 price target.

 hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

 gossamer-bio-q4-eps-021-inline-cash-cash-equivalents-and-marketable-securities-of-2964m-is-expected-to-provide-cash-runway-into-the-first-half-of-2026

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 6...

 on-march-4-2024-gossamer-bio-received-letter-stating-that-it-has-regained-compliance-with-minimum-bid-price-requirement-for-continued-listing-on-nasdaq

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1728117/000172811724000013/goss-20240304.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION